Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 9—September 2023
Dispatch

Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population

Liana R. Andronescu, Stephanie A. Richard, Eric D. Laing, Nora Pisanic, Si’Ana A. Coggins, Magdielis Gregory Rivera, Kate Kruczynski, Adam K. Saperstein, Jitendrakumar Modi, Jamie A. Fraser, Saira Shaikh, Christopher C. Broder, Timothy H. Burgess, Christopher D. Heaney, Simon D. Pollett, Eugene Millar, Christian L. Coles, and Mark P. SimonsComments to Author 
Author affiliations: Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA (L.R. Andronescu, S.A. Richard, E.D. Laing, S.A. Coggins, A.K. Saperstein, J.A. Fraser, S. Shaikh, C.C. Broder, T.H. Burgess, S.D. Pollett, E. Millar, C.L. Coles, M.P. Simons); The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda (L.R. Andronescu, S.A. Richard, S.A. Coggins, J.A. Fraser, S. Shaikh, S.D. Pollett, E. Millar, C.L. Coles); Johns Hopkins University, Baltimore, Maryland, USA (N. Pisanic, M. Gregory Rivera, K. Kruczynski, C.D. Heaney); Naval Health Clinic, Annapolis, Maryland, USA (A.K. Saperstein, J. Modi)

Main Article

Table 1

New SARS-CoV-2 infections detected among 79 study participants, by PCR and serologic test, at each specimen collection timepoint, US Naval Academy, Annapolis, Maryland, USA, August 2020–May 2021*

Test 2020 Aug (V1) 2020 Dec (V2) 2021 Feb (V3) 2021 May (V4)† Total
Saliva seroconversion‡ 0 2 3 13 18
Dried blood spot seroconversion 0 3 NA 16 19
PCR-positive 1 3 5 10 19

*Sample restricted to participants who had a PCR test on record (from screening or medically attended SARS-CoV-2) and were not seropositive at the first visit in August 2020. V1, V2, V3, and V4 note the visit timepoint that matches to the corresponding month. †Collection time is postvaccination; nucleocapsid IgG and not spike IgG seroconversion alone was used to measure infection. ‡Salivary nucleocapsid IgG positivity defined as receptor-binding domain IgG and nucleocapsid IgG positive; salivary spike IgG positivity used a receptor-binding domain target.

Main Article

Page created: July 31, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external